3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

I asked ChatGPT to settle the ISA v SIPP debate once and for all. It said…

Instead of working out whether an ISA or SIPP is the better tax wrapper, Harvey Jones called the robots in.…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

Amazon shares: overpriced or a possible bargain?

Christopher Ruane thinks Amazon shares look pricier than he normally likes -- but also reckons they could be a potential…

Read more »

Female Tesco employee holding produce crate
Investing Articles

In a jittery market, could Tesco shares be a defensive choice?

Could Tesco shares be a safe haven in nervous markets, given that consumers always need to eat? Our writer is…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

How much might £10,000 in Rolls-Royce shares soon be worth? Let’s ask the experts

Do Rolls-Royce shares look like a good buy after recent price falls? City analysts still appear bullish, but global events…

Read more »

Queen Street, one of Cardiff's main shopping streets, busy with Saturday shoppers.
Investing Articles

Take a deep breath! £10,000 invested in Greggs shares a year ago is now worth…

Someone who bought Greggs shares a year ago is nursing a paper loss. Our writer digs into the reasons why…

Read more »

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Whatever happened to the stock market crash?

The stock market refuses to crash, despite the Iran war. But Harvey Jones says lots of FTSE 100 shares have…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

BP’s share price will keep surging in 2026, according to this broker

BP’s share price is in a strong upward trend right now. And one City brokerage firm seems to believe that…

Read more »

Picture of an easyJet plane taking off.
Investing Articles

These 4 red flags mean I’m avoiding easyJet shares like the plague!

easyJet shares have slumped by around a quarter during the past month. Does this represent a dip-buying opportunity? Royston Wild…

Read more »